CpG oligodeoxynucleotides as vaccine adjuvants

Immunopotentiators in Modern Vaccines

Volumn , Issue , 2006, Pages 73-92

  McCluskie, Michael ^a   Weeratna, Risini ^a  

^a Coley Pharmaceutical Group ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35748944306     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088403-2/50006-X     Document Type: Chapter

References (150)

1. Ahmad-Nejad P., hacker H., Rutz M., Bauer S., Vabulas R.M., Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 2002, 32:1958-1968.
2. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2001, 2:675-680.
3. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
4. Alignani D., Maletto B., Liscovsky M., Ropolo A., Moron G., Pistoresi-Palencia M.C. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J. Leukoc. Biol. 2005, 77:898-905.
5. Allen D.B., Bielory L., Derendorf H., Dluhy R., Colice G.L., Szefler S.J. Inhaled corticosteroids: past lessons and future issues. J. Allergy Clin. Immunol. 2003, 112(Suppl.):S1-S40.
6. Amigorena S. Cancer immunotherapy using dendritic cell-derived exosomes. Medicina (Buenos Aires) 2000, 60(Suppl. 2):51-54.
7. An H., Yu Y., Zhang M., Xu H., Qi R., Yan X., Liu S., Wang W., Guo Z., Guo J., Qin Z., Cao X. Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology 2002, 106:38-45.
8. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J. Immunol. 2000, 164:3698-3704.
9. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., Persing D. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. 2004, 4:1129-1138.
10. Balsari A., Tortoreto M., Besusso D., Petrangolini G., Sfondrini L., Maggi R., Menard S., Pratesi G. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur. J. Cancer 2004, 40:1275-1281.
11. Banerjee B., Kelly K.J., Fink J.N., Henderson J.D., Bansal N.K., Kurup V.P. Modulation of airway inflammation by immunostimulatory CpG oligodeoxy-nucleotides in a murine model of allergic aspergillosis. Infect. Immunity 2004, 72:6087-6094.
12. Baral R.N., Saha A., Chatterjee S.K., Foon K.A., Krieg A.M., Weiner G.J., Bhattacharya-Chatterjee M. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol. Immunother. 2003, 52:317-327.
13. Barrios C., Brandt C., Berney M., Lambert P.H., Siegrist C.A. Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur. J. Immunol. 1996, 26:2666-2670.
14. Bauer S., Kirschning C.J., Hacker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 2001, 98:9237-9242.
15. Beckebaum S., Cicinnati V.R., Zhang X., Ferencik S., Frilling A., Grosse-Wilde H., Broelsch C.E., Gerken G. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escapes. Immunology 2003, 109:487-495.
16. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., Gockel C.M., Beagley K.W. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immunity 2004, 72:1019-1028.
17. Bohle B., Jahn-Schmid B., Maurer D., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol. 1999, 29:2344-2353.
18. Borchers A.T., Keen C.L., Gershwin M.E. Fatalities following allergen immunotherapy. Clin. Rev. Allergy Immunol. 2004, 27:147-158.
19. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 1998, 95:15553-15558.
20. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., Van Uden J., Martin-Orozco E., Gelfand E.W., Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyper-responsiveness in mice. J. Immunol. 1998, 161:7054-7062.
21. Chaput N., Schartz N.E., Andre F., Taieb J., Novault S., Bonnaventure P., Aubert N., Bernard J., Lemonnier F., Adema G., Adams M., Ferrantini M., Carpentier A.F., Escudier B., Tursz T., Angevin E., Zitvogel L. Exosomes as potent cell-free peptidebased vaccine: II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 2004, 172:2137-2146.
22. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13:29-60.
23. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 1999, 274:10689-10692.
24. Chu R.S., McCool T., Greenspan N.S., Schreiber J.R., Harding C.V. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect. Immunity 2000, 68:1450-1456.
25. Chuang T., Ulevitch R.J. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim. Biophys. Acta 2001, 1518:157-161.
26. Chuang T.H., Ulevitch R.J. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur. Cytokine Netw. 2000, 11:372-378.
27. Cookson W.O., Moffatt M.F. Asthma: an epidemic in the absence of infection?. Science 1997, 275:41-42.
28. Cooper C.L., Davis H.L., Angel J.B., Morris M.L., Efler S.M., Sequin I., Krief A.M., Cameron D.W. CpG 7909 is safe and highly effective as an adjuvant to HBV vaccine in HIV seropositive adults. AIDS 2005, in press.
29. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., Cameron D.W., Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist iligodeoxynucleotide, as adjuvant to Engerix-B((R)) HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol 2004, 24:693-701.
30. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., Laframboise C., Al Adhami M.J., Khaliq Y., Seguin I., Cameron D.W. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22:3136-3143.
31. Davila E., Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 2000, 165:539-547.
32. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003, 63:3281-3288.
33. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L.aiSchorr J., Krieg A.M., Weeratna R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J. Immunol. 1999, 162, 3103]. J. Immunol. 1998, 160:870-876.
34. Davis H.L., Suparto I.I., Weeratna R.R., Jumintarto, Iskandriati D.D., Chamzah S.S., Ma'ruf A.A., Nente C.C., Pawitri D.D., Krieg A.M., Heriyanto, Smits W., Sajuthi D.D. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000, 18:1920-1924.
35. Dumais N., Patrick A., Moss R.B., Davis H.L., Rosenthal K.L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 2002, 186:1098-1105.
36. Dummer R. GVAX (Cell Genesys). Curr. Opin. Invest. Drugs 2001, 2:844-848.
37. Eastcott J.W., Holmberg C.J., Dewhirst F.E., Esch T.R., Smith D.J., Taubman M.A. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 2001, 19:1636-1642.
38. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 1999, 163:6762-6768.
39. Fantuzzi L., Purificato C., Donato K., Belardelli F., Gessani S. Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. J. Virol. 2004, 78:9763-9772.
40. Freidag B.L., Melton G.B., Collins F., Klinman D.M., Cheever A., Stobie L., Suen W., Seder R.A. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immunity 2000, 68:2948-2953.
41. Fujieda S., Iho S., Kimura Y., Yamamoto H., Igawa H., Saito H. Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes. Am. J. Respir. Crit. Care Med. 2000, 162:232-239.
42. Furumoto K., Soares L., Engleman E.G., Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 2004, 113:774-783.
43. Galbraith W.M., Hobson W.C., Giclas P.C., Schechter P.J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 1994, 4:201-206.
44. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 2001, 166:3451-3457.
45. Gewirtz A.T., Navas T.A., Lyons S., Godowski P.J., Madara J.L. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 2001, 167:1882-1885.
46. Gibson S.J., Lindh J.M., Riter T.R., Gleason R.M., Rogers L.M., Fuller A.E., Oesterich J.L., Gorden K.B., Qiu X., McKane S.W., Noelle R.J., Miller R.L., Kedl R.M., Fitzgerald-Bocarsly P., Tomai M.A., Vasilakos J.P. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002, 218:74-86.
47. Gill R.F., Montgomery P.C. Enhancement of rat tear IgA antibody responses following intranasal immunization with antigen and CpG ODN. Curr. Eye Res. 2002, 24:228-233.
48. Grosjean I., Caux C., Bella C., Berger I., Wild F., Banchereau J., Kaiserlian D. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J. Exp. Med. 1997, 186:801-812.
49. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.
50. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., Rothenfusser S., Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 2003, 33:1633-1641.
51. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., Eng J.K., Akira S., Underhill D.M., Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
52. Heckelsmiller K., Beck S., Rall K., Sipos B., Schlamp A., Tuma E., Rothenfusser S., Endres S., Hartmann G. Combined dendritic cell- and CpG oligonucleotidebased immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 2002, 32:3235-3245.
53. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of singlestranded RNA via Toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
54. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 1989, 169:59-72.
55. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
56. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 2002, 3:196-200.
57. Hiraoka K., Yamamoto S., Otsuru S., Nakai S., Tamai K., Morishita R., Ogihara T., Kaneda Y. Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 2004, 173:4297-4307.
58. Holmgren J., Harandi A.M., Czerkinsky C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines 2003, 2:205-217.
59. Horner A.A., Raz E. Immunostimulatory sequence oligodeoxynucleotide: a novel mucosal adjuvant. Clin. Immunol. 2000, 95(Pt 2):S19-S29.
60. Horner A.A., Ronaghy A., Cheng P.M., Nguyen M.D., Cho H.J., Broide D., Raz E. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 1998, 190:77-82.
61. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
62. Jahn-Schmid B., Wiedermann U., Bohle B., Repa A., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J. Allergy Clin. Immunol. 1999, 104:1015-1023.
63. Jiang J.Q., Patrick A., Moss R.B., Rosenthal K.L. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol. 2005, 79:393-400.
64. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., Davis H.L., Krieg A.M., Hoffman S.L. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999, 17:3065-3071.
65. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., Hayashi T., Takabayashi K., Barenholz Y., Kedar E. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20:3342-3354.
66. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-869.
67. Kim S.K., Ragupathi G., Musselli C., Choi S.J., Park Y.S., Livingston P.O. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 2000, 18:597-603.
68. Kim T.G., Kim C.H., Won E.H., Bae S.M., Ahn W.S., Park J.B., Sin J.I. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 2004, 112:117-125.
69. Kim T.Y., Myoung H.J., Kim J.H., Moon I.S., Kim T.G., Ahn W.S., Sin J.I. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res. 2002, 62:7234-7240.
70. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., Thorne P.S., Krieg A.M. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 1998, 160:2555-2559.
71. Kline J.N., Krieg A.M., Waldschmidt T.J., Ballas Z.K., Jain V., Businga T.R. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J. Allergy Clin. Immunol. 1999, 104:1258-1264.
72. Kline J.N., Kitagaki K., Businga T.R., Jain V.V. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 283:L170-L179.
73. Kobayashi H., Horner A.A., Takabayashi K., Nguyen M.D., Huang E., Cinman N., Raz E. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol. 1999, 198:69-75.
74. Kochling J., Konig-Merediz S.A., Stripecke R., Buchwald D., Korte A., Von Einsiedel H.G., Sack F., Henze G., Seeger K., Wittig B., Schmidt M. Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clin. Cancer Res. 2003, 9:3142-3149.
75. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 2002, 347:1645-1651.
76. Kovarik J., Bozzotti P., Love-Homan L., Pihlgren M., Davis H.L., Lambert P.H., Krieg A.M., Siegrist C.A. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 1999, 162:1611-1617.
77. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
78. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts?. Nature Med. 2003, 9:831-835.
79. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 2004, 6:88-95.
80. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
81. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 2004, 27:460-471.
82. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., Giese T., Engelmann H., Endres S., Krieg A.M., Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 2001, 31:3026-3037.
83. Kruse M., Rosorius O., Kratzer F., Stelz G., Kuhnt C., Schuler G., Hauber J., Steinkasserer A. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J. Virol. 2000, 74:7127-7136.
84. Kuwana M., Kaburaki J., Wright T.M., Kawakami Y., Ikeda Y. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur. J. Immunol. 2001, 31:2547-2557.
85. Kwant A., Rosenthal K.L. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004, 22:3098-3104.
86. Leichman G., Gravenor D., Albert G., Schmalbach T.A. TLR9 Cpg Immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLC), a randomized, controlled phase II study. J. Clin. Oncol. 2004, 22:1726. 14S.
87. Lien E., Means T.K., Heine H., Yoshimura A., Kusumoto S., Fukase K., Fenton M.J., Oikawa M., Qureshi N., Monks B., Finberg R.W., Ingalls R.R., Golenbock D.T. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest 2000, 105:497-504.
88. Lipford G.B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol. 2000, 165:1228-1235.
89. Liu H.M., Newbrough S.E., Bhatia S.K., Dahle C.E., Krieg A.M., Weiner G.J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocytemacrophage colony-stimulating factor. Blood 1998, 92:3730-3736.
90. Magone M.T., Chan C.C., Beck L., Whitcup S.M., Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol. 2000, 30:1841-1850.
91. Maletto B., Ropolo A., Moron V., Pistoresi-Palencia M.C. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. J. Leukoc. Biol. 2002, 72:447-454.
92. Manning B.M., Enioutina E.Y., Visic D.M., Knudson A.D., Daynes R.A. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp. Gerontol. 2001, 37:107-126.
93. Marshall J.D., Fearon K., Abbate C., Subramanian S., Yee P., Gregorio J., Coffman R.L., Van Nest G. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 2003, 73:781-792.
94. Martin P., Del Hoyo G.M., Anjuere F., Arias C.F., Vargas H.H., Fernandez L., Parrillas V., Ardavin C. Characterization of a new subpopulation of mouse CD8alpha+B220+dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 2002, 100:383-390.
95. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 1998, 161:4463-4466.
96. McCluskie M.J., Davis H.L. CpG DNA as mucosal adjuvant. Vaccine 1999, 18:231-237.
97. McCluskie M.J., Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 2000, 19:413-422.
98. McCluskie M.J., Wen Y.M., Di Q., Davis H.L. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol. 1998, 11:245-252.
99. McCluskie M.J., Weeratna R.D., Krieg A.M., Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 2000, 19:950-957.
100. McCluskie M.J., Weeratna R.D., Clements J.D., Davis H.L. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 2001, 19:3759-3768.
101. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10:75-88.
102. Medina E., Guzman C.A. Modulation of immune responses following antigen administration by mucosal route. FEMS Immunol. Med. Microbiol. 2000, 27:305-311.
103. Merad M., Sugie T., Engleman E.G., Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002, 99:1676-1682.
104. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 2002, 168:1212-1218.
105. Milas L., Mason K.A., Ariga H., Hunter N., Neal R., Valdecanas D., Krieg A.M., Whisnant J.K. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004, 64:5074-5077.
106. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998, 16:1216-1224.
107. Mui B., Raney S.G., Semple S.C., Hope M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 2001, 298:1185-1192.
108. Nesburn A.B., Ramos T.V., Zhu X., Asgarzadeh H., Nguyen V., Benmohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 2005, 23:873-883.
109. Nicklin P.L., Bayley D., Giddings J., Craig S.J., Cummins L.L., Hastewell J.G., Phillips J.A. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes. Pharm. Res. 1998, 15:583-591.
110. O'Hagan D.T., MacKichan M.L., Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng 2001, 18:69-85.
111. O'Rourke M.G., Schmidt C.W., O'Rourke T.R., Ellem K.A. Immunotherapy, including gene therapy, for metastatic melanoma. Aust. NZ J. Surg. 1997, 67:834-841.
112. Olszewska W., Partidos C.D., Steward M.W. Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect. Immunity 2000, 68:4923-4929.
113. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 2003, 77:13156-13160.
114. Rauthan M., Kaur R., Appaiahgari M.B., Vrati S. Oral immunization of mice with Japanese encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies. Microbes. Infect. 2004, 6:1305-1311.
115. Rhee S.H., Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J. Biol. Chem. 2000, 275:34035-34040.
116. Rieger R., Kipps T.J. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 2003, 63:4128-4135.
117. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA 1998, 95:588-593.
118. Sajic D., Ashkar A.A., Patrick A.J., McCluskie M.J., Davis H.L., Levine K.L., Holl R., Rosenthal K.L. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J. Med. Virol. 2003, 71:561-568.
119. Sandler A.D., Chihara H., Kobayashi G., Zhu X., Miller M.A., Scott D.L., Krieg A.M. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003, 63:394-399.
120. Schetter C., Vollmer J. Toll-like receptors involved in the response to microbial pathogens: development of agonists for Toll-like receptor 9. Curr. Opin. Drug Discov. Devel. 2004, 7:204-210.
121. Schiller J.T., Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat. Rev. Microbiol. 2004, 2:343-347.
122. Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 1999, 274:17406-17409.
123. Serebrisky D., Teper A.A., Huang C.K., Lee S.Y., Zhang T.F., Schofield B.H., Kattan M., Sampson H.A., Li X.M. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J. Immunol. 2000, 165:5906-5912.
124. Sher A. Schistosomiasis. Parasitizing the cytokine system. Nature 1992, 356:565-566.
125. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 2000, 164:5575-5582.
126. Siegrist C.A., Pihlgren M., Tougne C., Efler S.M., Morris M.L., Al-Adhami M.J., Cameron D.W., Cooper C.L., Heathcote J., Davis H.L., Lambert P.H. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23:615-622.
127. Sparwasser T., Vabulas R.M., Villmow B., Lipford G.B., Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 2000, 30:3591-3597.
128. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P. Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115:739-746.
129. Spiegelberg H.L., Horner A.A., Takabayashi K., Raz E. Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr. Opin. Allergy Clin. Immunol. 2002, 2:547-551.
130. Stern B.V., Boehm B.O., Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J. Immunol. 2002, 168:6099-6105.
131. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 1999, 162:6284-6293.
132. Switaj T., Jalili A., Jakubowska A.B., Drela N., Stoksik M., Nowis D., Basak G., Golab J., Wysocki P.J., Mackiewicz A., Sasor A., Socha K., Jakobisiak M., Lasek W. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer. Res. 2004, 10(Pt 1):4165-4175.
133. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., Klinman D.M. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 2001, 167:3555-3558.
134. Takeuchi O., Kawai T., Sanjo H., Copeland N.G., Gilbert D.J., Jenkins N.A., Takeda K., Akira S. TLR6: a novel member of an expanding toll-like receptor family. Gene 1999, 231:59-65.
135. Thomsen L.L., Topley P., Daly M.G., Brett S.J., Tite J.P. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004, 22:1799-1809.
136. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., Kagey-Sobotka A., Creticos P.S., Lichtenstein L.M., Spiegelberg H.L., Raz E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 2000, 106(Pt 1):124-134.
137. Tsubouchi E., Akbar Sk.Md.Fazle, Horiike N., Morikazu O. Infection and dysfuncation of circulating blook dendritic cells and their subsets in chronic hepatitis C virus infection. J. Gastroenterol. 2004, 39:754-762.
138. Vasilakos J.P., Smith R.M., Gibson S.J., Lindh J.M., Pederson L.K., Reiter M.J., Smith M.H., Tomai M.A. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol. 2000, 204:64-74.
139. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., Krieg A.M. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34:251-262.
140. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leshmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc. Natl. Acad. Sci. USA 1999, 96:6970-6975.
141. Wang X.S., Sheng Z., Ruan Y.B., Guang Y., Yang M.L. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J. Gastroenterol. 2005, 11:1220-1224.
142. Wang Y., Wang W., Li N., Yu Y., Cao X. Activation of antigen-presenting cells by immunostimulatory plant DNA: a natural resource for potential adjuvant. Vaccine 2002, 20:2764-2771.
143. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18:1755-1762.
144. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., Davis H.L. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult
145. Weigel B.J., Rodeberg D.A., Krieg A.M., Blazar B.R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 2003, 9:3105-3114.
146. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 1997, 94:10833-10837.
147. World Health Organization World Health Organization. Global Alliance for Vaccines and Immunization (GAVI) 2001, Fact Sheet No. 169.
148. Yi A.K., Hornbeck P., Lafrenz D.E., Krieg A.M. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 1996, 157:4918-4925.
149. Yi A.K., Chang M., Peckham D.W., Krieg A.M., Ashman R.F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 1998, 160:5898-5906.
150. Yoshimura A., Lien E., Ingalls R.R., Tuomanen E., Dziarski R., Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 1999, 163:1-5.